Intermountain Precision Genomics Core Laboratory announced the expansion of RxMatch™, a pharmacogenomics service, to all Intermountain Healthcare providers. Originally launched as an antidepressant panel in September 2017, the new RxMatch™ Comprehensive Panel expands the gene targets from 36 to 97.
The new RxMatch™ Comprehensive Panel includes opioids, statins, immunosuppressants, anti-depressants and many more. The results, powered by Coriell Life Sciences, seamlessly integrate genomic medicine into clinical care while managing the breadth of information that is obtained through genomic sequencing. David Loughmiller, Laboratory Manager for Intermountain Precision Genomics, said, “The objective of this project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication.”
Once the sample is received, a comprehensive report is available within about a week. One doctor who viewed an example of the report said, “We should have a report like this for all of our patients.” Intermountain Healthcare is widely recognized as a leader in transforming healthcare through high quality and sustainable costs.
Leaders at Intermountain Precision Genomics see RxMatch™ as a commitment to Intermountain Healthcare’s aspiration to “Become the most genetically advanced healthcare system in the world.”
To request training, or to order an RxMatch™ Starter Kit for a physician office, please call (435) 251-5780 or visit www.Intermountain.com/RxMatch.